

Docket No.: 251865US0CONT

OBLON
SPIVAK
MCCLELLAND
MAIER
&
NEUSTADT
P.C.

ATTORNEYS AT LAW

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/825,127

Applicants: Naoyuki FUKUCHI, et al.

Filing Date: April 16, 2004

For: SUBSTANCE WITH ANTITHROMBIC ACTIVITY

AND METHOD FOR DETECTING GLYCOCALICIN

Group Art Unit: 1641

Examiner:

SIR:

Attached hereto for filing are the following papers:

Amendment and Response to Restriction and Election of Species Requirement

Our check in the amount of **0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Customer Number 22850

(703) 413-3000 (phone) (703) 413-2220 (fax) Vincent K. Shier, Ph.D. Registration No. 50,552



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

NAOYUKI FUKUCHI, ET AL : EXAMINER: JUNG, U.

SERIAL NO: 10/825,127

FILED: APRIL 16, 2004 : ART UNIT: 1641

FOR: SUBSTANCE WITH ANTITHROMBIC ACTIVITY AND METHOD FOR

DETECTING GLYCOKALLIDIN

AMENDMENT AND RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction and Election of Species Requirement mailed on December 14, 2006, Applicants provisionally elect Group III, Claims 31-35, drawn to a chimeric protein. With the election of Group III, and election of species is not required.

REMARKS

The Examiner is restricting this application to a single group of inventions for further prosecution and is requiring the election of one of the following Groups:

Group I: Claims 21-25, drawn to a method for detecting binding of von

Willebrand factor and glycoprotein lb or inhibition of the binding by correlating a detecting of Fc region of immunoglobulin molecule with the binding of von Willebrand factor and glycoprotein lb or inhibition of the binding, classified in class 435, subclass 7.1, for example;

Group II: Claims 26-30, drawn to a method for detecting binding of von

Willebrand factor and glycoprotein lb or inhibition of the binding by using labeled and unlabeled von Willebrand factor, classified in class

435, subclass 7.93, for example; and